Report of Foreign Issuer (6-k)
August 16 2017 - 1:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2017
Commission
File Number 001-37381
MEDIGUS
LTD.
(Translation of registrant’s name into English)
Omer
Industrial Park, No. 7A, P.O. Box 3030, Omer 8496500, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
EXPLANATORY
NOTE
On August 15, 2017, Medigus Ltd., or the Company, held an annual general meeting of its shareholders, or the Meeting, at the offices
of the Company at Omer Industrial Park, Building No. 7A, Omer, Israel. At the Meeting, shareholders voted on the proposals
detailed in the Company’s proxy statement for the Meeting that was attached as Exhibit 99.1 to a Report of Foreign Private
Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission on July 10, 2017. As of July
10, 2017, the record date for the Meeting, there were 146,084,334 ordinary shares issued, outstanding and entitled to vote at
the Meeting. There were 21,977,697 ordinary shares present in person or represented by proxy at the Meeting, representing
15.04% of the issued and outstanding ordinary shares of the Company, and a quorum was present for all issues voted on at the Meeting.
At the Meeting, all proposals were approved by the requisite vote of the Company’s shareholders, except for the proposal
to increase the aggregate number of ordinary shares authorized for issuance under the Company’s 2013 Share Option and Incentive
Plan.
This
Form 6-K is incorporated by reference into the Company’s Registration Statement on Form F-3 filed with the Securities and
Exchange Commission on August 24, 2016 (Registration No. 333- 213280) and its Registration Statement on Form S-8 filed with the
Securities and Exchange Commission on September 9, 2015 (Registration No. 333-206803).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
MEDIGUS
LTD.
|
|
|
|
Date:
August 16, 2017
|
By:
|
/s/
Oded Yatzkan
|
|
|
Oded
Yatzkan
|
|
|
Chief
Financial Officer
|
3
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024